Dear Shareholders,
As we reflect on 2024, your trust and support have been pivotal to our success in building a strong platform for Nordic life sciences companies seeking to expand into the U.S. market.
This year, we have achieved significant milestones, including our uplist to the OTCQB, enhancing our ability to execute growth plans by making our shares more appealing to acquisition and recruiting targets. We also welcomed Peter Severin as Chairman of the Board, whose invaluable experience will guide us as we pursue our mission to acquire majority stakes in Nordic and U.S.-based life sciences companies.
We finalized the acquisition of Orocidin A/S, which has become a wholly-owned subsidiary of Nordicus. This all-stock transaction underscores our commitment to forming strategic partnerships with strong growth potential. Orocidin is a preclinical stage biotech company developing QR-01, a first-of-its-kind treatment for periodontitis with a novel antimicrobial and immunomodulatory mechanism. Orocidin expects to begin pilot efficacy studies in 2025, marking an exciting new chapter for Orocidin and Nordicus.
Additionally, we entered into a consultancy agreement in June with Denmark-based Bio-Convert ApS, a preclinical stage biotech company advancing a groundbreaking treatment for oral leukoplakia, a potentially malignant disorder linked to oral cancer. In Q4 we completed our acquisition of Bio-Convert which is now a wholly owned subsidiary. Bio-Convert is set to begin pilot efficacy studies in 2025.
Thank you for your continued confidence and investment in Nordicus. As we look ahead to 2025, the foundation built in 2024 will set the stage for continued success in the years ahead. Our focus remains on delivering exceptional value to our portfolio companies and stakeholders by leveraging our expertise and strategic partnerships to support innovative businesses navigating the complexities of market entry and growth.
We are excited about the opportunities that lie ahead and look forward to sharing more successes with you in the coming year.
With gratitude,
Henrik Rouf
Chief Executive Officer, Nordicus Partners
